Global Atomic (GLO.TO) C$0.77 pre-market: Mar 26 earnings may move stock

Global Atomic Corporation (GLO.TO) trades at C$0.77 pre-market as investors focus on the company’s earnings due on 26 March 2026. The GLO.TO stock is down -4.94% today on volume of 1,620,338. With uranium project updates from the Dasa deposit expected, the report could change near-term sentiment. We review valuation, technicals, Meyka AI grade, and a model forecast to help frame risk ahead of the TSX release.

Earnings context and key catalysts

Global Atomic (GLO.TO) reports on 26 March 2026. Investors will watch production guidance for the Dasa uranium project and any update on offtake or financing. Management comments on capex, timing for first production, and Niger operational risk will matter. The company also sells zinc concentrates, so zinc market commentary may appear.

GLO.TO stock price action and technical snapshot

The stock opened at C$0.78, trading between C$0.74 and C$0.81 today, with a previous close of C$0.81. Key technicals show RSI 41.83 and MACD histogram -0.02, suggesting weak momentum. Short-term resistance sits near the 50-day average at C$0.82 and the Bollinger middle at C$0.88. Support lies at today’s low C$0.74 and the 52-week low C$0.44.

Fundamentals and valuation for GLO.TO stock

On fundamentals Global Atomic posts EPS -0.05 and a trailing PE of -15.20, reflecting negative earnings. Book value per share is C$0.87 and price-to-book is 0.90, below Basic Materials peers. Current ratio is 0.22, indicating tight near-term liquidity, while debt-to-equity is low at 0.01. Free cash flow is negative, and operating cash flow per share is -0.02. These metrics frame earnings risk if cash burn or capex needs increase.

Meyka AI rates GLO.TO with a score out of 100

Meyka AI rates GLO.TO with a score out of 100: 61.53 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparison, financial growth, key metrics, forecasts, and analyst consensus. Third-party company rating shows a C / Sell view dated 2026-03-23, highlighting mixed signals between balance-sheet strength and profitability. These grades are not guarantees and are not financial advice.

Price forecast scenarios and Meyka AI outlook

Meyka AI’s forecast model projects C$1.01 (monthly) and C$1.06 (quarterly). Versus the current price of C$0.77, the quarterly projection implies upside of 37.66% and the monthly projection implies upside of 31.17%. A downside scenario to the 52-week low C$0.44 implies -42.86%. Forecasts are model-based projections and not guarantees.

What to watch into the GLO.TO earnings report

Focus items for the report: updated production timeline for Dasa, final capex estimates, cash position, off-take agreements, and Niger permitting progress. Also watch management guidance on zinc concentrate sales and any change to share count. Sector context matters: Basic Materials peers trade at higher PB values, so relative valuation will shape analyst reaction. For real-time data see our Meyka stock page and recent market coverage.

Final Thoughts

GLO.TO stock trades at C$0.77 pre-market with earnings due 26 March 2026. The result can move shares materially. Fundamentals show low liquidity and negative EPS, but book value and low debt moderate balance-sheet concerns. Technicals point to weak momentum, while Meyka AI gives a B (61.53) grade and a model target of C$1.06 over the next quarter. That target implies 37.66% upside vs today’s price. A conservative monthly projection is C$1.01, or 31.17% upside. Conversely, a move back to the 52-week low of C$0.44 would erase -42.86%. Use the earnings release to test management’s execution plan and cash needs. Meyka AI, our AI-powered market analysis platform, will update the model after the report. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.